First Half Fiscal Year 2004 Financial Results. Eisai Co., Ltd.
|
|
- Norman Bryant
- 6 years ago
- Views:
Transcription
1 1 First Half Fiscal Year 2004 Financial Eisai Co., Ltd.
2 Consolidated Performance for First Half FY 2004 (billions of yen, %) 2 FY2003 1H FY2004 1H % % Change Net Sales Cost of sales Gross Margin R&D Expenses SG&A Expenses Operating Income Ordinary Income Net Income EPS (Yen)
3 Consolidated Performance for Second Quarter FY 2004 FY2004 1Q FY2004 2Q (billions of yen, %) 3 % % Net Sales Cost of sales Gross Margin R&D Expenses SG&A Expenses Operating Income Ordinary Income Net Income EPS (Yen)
4 Sales of Major Products 4 (billions of yen, %) Product Name Area FY2004 1Q FY2004 2Q FY2004 1H Aricept Alzheimer s Disease Total Japan U.S Treatment Millions of Dollars Europe Asia Aciphex/ Pariet Proton Pump Inhibitor Total Japan U.S. Millions of Dollars Europe Asia The average dollar rate during first half of FY2004 was yen and that during first half of FY2003 was yen.
5 Sales to Customers by Geographic Area 5 (billions of yen, %) FY2003 FY2004 1H 1H % % Change Japan North America Europe Asia and Others Overseas Total Total
6 Operating Income by Geographic Area 6 (Pre-royalty deduction) FY2003 1H FY2004 1H (billions of yen, %) % % Change Japan (5.5) North America Europe Asia and Others Overseas Total Sub-Total (1.7) Eliminations (5.5) (3.2) 2.3 Total
7 Performance of Eisai Inc. (millions of dollars, %) 7 FY2003 1H FY2004 1H % % Change Net Sales Aricept Aciphex Zonegran Operating Income Net Income Operating Income (Pre-royalty Deduction)
8 8 Consolidated Free Cash Flow (billions of yen) Cash Flow from Operating Activities Capital Expenditure Free Cash Flow Change Change Change FY2002 1H 19.6 (13.6) (14.2) (3.9) 5.3 (17.5) FY2003 1H (9.8) FY2004 1H 40.8 (5.1) (24.2) (14.3) 16.6 (19.4)
9 Further Globalization 9 Established European Regional Headquarters Eisai Europe Limited Expand into new markets and strengthen management Current Operations India EU Established a subsidiary in India Eisai Pharmaceuticals India Private Limited Functions include filing for approval, clinical development, consignment of manufacturing, promotion and marketing products, and importation of drug substance
10 U.S. Aricept Sales and Prescription Growth Trends ( %) 10 April to June 2004/2003 July to September 2004/2003 April to September 2004/2003 Sales NRx TRx ( Source: IMS NPA Plus, Retail, Sales comparison is based on dollar figures)
11 U.S. Aciphex Sales and Prescription Growth Trends ( %) 11 April to June 2004/2003 July to September 2004/2003 April to September 2004/2003 Sales NRx TRx ( Source: IMS NPA Plus, Retail, Sales comparison is based on dollar figures)
12 Steady Growth of Japanese Business 12 Growth Rate Sales growth rate in Japan April-September 2004, IMS Prescription pharmaceuticals in Japan Market share by sales Market Average 102.6% Market Share 1H FY % Eisai 106.6% 1H FY % April-September 2003 and 2004, IMS Ranking of Manufacturers Prescription pharmaceuticals in Japan FY2003 8th 1H FY2004 7th April 2003-March 2004, April-September 2004, IMS
13 13 Achievement of Pariet in Japan 1. Established as the top branded PPI in university hospitals 2. Consistent acid suppression and therapeutic efficacy, demonstrated in data 1) The therapeutic effects of rabeprazole at a dose of 10mg on reflux esophagitis may not be influenced by CYP2C19 polymorphism Authors: Ken Ariizumi et al, Japanese Journal of Gastroenterology. 101(Suppl.) A193, ) The therapeutic effects of rabeprazole in patients with H. pylori positive or negative gastro-esophageal reflux disease Authors: Toshihito Saitoh et al, Japanese Journal of Gastroenterology. 101(Suppl.), P021, ) Anti-gastric acid secretion effects of three proton pump inhibitors (rabeprazole(10,20), omeprazole(10,20), lansoprazole(15,30)) Authors: Tomohiko Shimatani et al, the Journal of Japanese Society of Gastric Secretion Research, 36, 55-58, More patients with GERD identified through ongoing educational efforts
14 Growth Strategy for Pariet in Japan - To Be Most Preferred Branded PPI by Patients Expand market by educating patients about GERD Promote the diagnosis of GERD by utilizing FSSG interview sheet Promote the diagnosis and evaluation of treatment efficacy by using VAS Educate patients via web broadcasting Educate patients via mass media 2. Gain share in the PPI market Increase medical reps (1,200 MRs) in FY2005 Establish prescription and treatment guideline by each department in hospitals Present efficacy and safety data based on comparative evidence Gaining market share in PPI Market FY B FY B 3. Seek further product potential through additional indications H. pylori eradication (submission is expected in FY2004) Non-erosive GERD (submission is expected in FY2005) Expand market by educating patients about GERD FSSG: Frequency Scale for the Symptom of GERD VAS: Visual Analogue Scale
15 Newly Launched Products In First Half FY2004 Zonegran (Epilepsy) April 28, 2004, U.S. 15 Aricept D Tablets (Rapid Disintegrating Tablet) July 1, 2004, Japan Apnission Inj. (Apnea in Premature infants) July 1, 2004, Japan Neophyllin Inj. prefilled soft bag 250mg (Additional Formulation) July 1, 2004, Japan Warfarin 0.5mg Tablet (Additional Formulation) May 10, 2004, Japan
16 16 U.S. Zonegran Zonegran was transitioned smoothly from Elan to Eisai. 90 Elan sales personnel joined Eisai upon deal execution. Zonegran sales have been booked by Eisai Inc. since April 28th and achieved $56 million in first half FY2004 (five months). Zonegran off to a strong start for FY2004 sales target of $110 million. Zonegran contributed to an increase in profit even after absorbing amortization costs. Epilepsy will be a therapeutic area of focus with Zonegran, Cerebyx, rufinamide, and E2007. Zonegran was filed for approval under the centralised procedure in the E.U. in November 2003.
17 Regulatory Achievements In First Half FY2004 Approved Pariet - On-demand therapy of symptomatic GORD - Amendments to the Posology and Method of Administration (EU, April) - Zollinger-Ellison Syndrome - Additional indication (EU, June) Aricept - Orally Disintegrating Tablet - Additional formulation (US, October) - Liquid - Additional formulation (US, October) Coretec - Prefilled softbag -Additional formulation (Japan, September) 17 Submitted Zonegran (E2090) - Application was transferred from Elan (EU, April) - Application was submitted in November, 2003 Aricept - Liquid - Additional formulation (EU, May) Blue: Achievements during second quarter FY2004 and subsequent events
18 Advances in Development Phase In First Half FY Phase III KES524 (generic name: sibutramine) Phase III initiated (Japan) Pariet Non-erosive GERD Phase III initiated (Japan) Phase II TVP-1012 (generic name: rasagiline) Phase II initiated (US) Alzheimer s disease (additional indication) E7389 Cancer/Breast Cancer Phase II initiated (US) E7070 Cancer/Gastric Cancer Phase I/II initiated (Japan) New Compound Ravuconazole - Triazole-type antifungal agent originally synthesized by Eisai - Initiate an independent development program for ravuconazole upon termination of the licensing agreement with BMS Discontinued E3309 H. pylori eradication Phase I: Contract expiration resolved Blue: Achievements during second quarter FY2004 and subsequent events Excludes compounds that have not changed phase in first half FY2004.
19 Advances in Development Phase -Newly Initiated Clinical Studies- 19 TVP-1012 (rasagiline) E3030 E7080 E3024 Alzheimer s disease (additional indication) Irreversible monoamine oxidase type B (MAO-B) inhibitor Diabetes Control glucose level by dual agonizing PPAR alpha-gammma Cancer Diabetes Indication Oral angiogenesis inhibitor (VEGFR tyrosine kinase inhibitor) Control glucose level by inhibiting DPP (dipeptidyl peptidase) IV Phase II initiated (US) Status Phase I initiated (US, Japan) Phase I in preparation (US, EU) Phase I in preparation (Japan)
20 Key Global POC Projects 20 E2007: AMPA Receptor Antagonist Parkinson s disease Epilepsy Multiple Sclerosis Region EU US EU Stage Phase IIb in progress Phase IIb in preparation Phase IIa completed E7070 (indisulam): Cell Cycle G1 Phase Targeting Agent Mono/Combo Region Stage Combo Breast cancer Mono Combo US EU Phase IIb in progress Phase II in preparation - capecitabine Colorectal cancer Combo Combo EU EU Phase II in preparation Phase II in progress capecitabine irinotecan NSCLC Combo EU Phase II in progress carboplatin Gastric cancer Mono JP Phase I/II initiated - Blue: Studies expected to complete POC in FY2004
21 Key Global POC Projects 21 E7389: Tubulin Polymerization Inhibitor Mono/Combo Region Stage Mono US Phase I in progress Breast cancer Mono US Phase II initiated NSCLC Mono US Phase II in preparation E5564 (eritoran): Endotoxin Antagonist Sepsis Prevention of endotoxin-related complication after coronary artery bypass graft surgery (CABG) Prevention of endotoxin-related complication after coronary artery bypass graft surgery (CABG) Region US EU EU Stage Phase II (3 rd Stage, high dose) in progress Phase IIa completed Phase IIb in progress Blue: Studies expected to complete POC in FY2004
22 Aricept Lifecycle Management 22 Vascular Dementia (US) Filing Submit Additional Data in the U.S. Re-file in the E.U. in FY2005 Severe Alzheimer s (US, EU, Japan) Phase III Filing Expected in FY2005 Dementia Associated with Parkinson s Disease (EU) Phase III Filing Expected in FY2005 Mild Cognitive Impairment (US) Phase III Migraine Prophylaxis (US, EU) Phase II Orally Disintegrating Tablet (US) Approved in October, 2004 Liquid Formulation (US) Approved in October, 2004 Orally Disintegrating Tablet (EU) Filed in 2003 Liquid Formulation (EU) Filed in 2004
23 Pariet/Aciphex Lifecycle Management 23 Eradication of H. pylori (US, EU) Symptomatic GERD (US, EU) EU 2000 US 2002 EU 2001 US 2002 Approved Approved Maintenance Therapy for GERD (Japan) Approved in 2003 On-demand Therapy for Symptomatic GORD (EU) Approved in April, 2004 Zollinger-Ellison Syndrome (EU) Approved in July, 2004 Eradication of H. pylori (Japan) Non-erosive GERD (Japan) Phase III Phase III Filing Expected in FY2004 Filing Expected in FY2005 Intermittent Therapy for Symptomatic GERD (US) Phase II
24 Global Filing Plan NME (New Molecular Entity) and LCM (Lifecycle Management) 24 FY2005 FY2004 Filed FY2006 FY2007 FY2008 E5564 (Sepsis, US and EU) E7070 (Gastric cancer, JP) E5564 (Prevention of endotoxin-related complications after coronary artery bypass graft surgery, US and EU) KES524 (Obesity Management, JP) E2007 (PD, US and EU) E7070 (Breast cancer, US and EU) E7389 (Breast cancer, US) D2E7 (Rheumatoid arthritis, JP) Aricept (Severe AD, US and EU) E2014 (Cervical dystonia, JP) Aricept (Dementia associated with PD, EU) E7210 (Contrast medium, JP) Aricept (Vascular dementia, submit additional data in US and re-file in EU) Pariet (Non-erosive GERD, JP) rufinamide (Epilepsy, US and EU) Pariet (H.pylori eradication, JP) Zonegran (E2090: Epilepsy, EU) Aricept (Orally disintegrating tablets, EU) Careram (T-614 : Rheumatoid arthritis, JP) Aricept (Liquid, EU)
25 Financial Forecast for FY (billions of yen, %) FY2003 FY2004 Estimates Net Sales R&D Expenses Operating Income (R&D Expenses + Operating Income Ratio) 30.4% 31.0% - Net Income EPS (Yen) Dividends (Yen ) DOE (%)
Fiscal Year 2003 Consolidated 1 st Quarter Business Performance. Eisai Co., Ltd.
Fiscal Year 2003 Consolidated 1 st Quarter Business Performance Eisai Co., Ltd. 1 Consolidated 1 st Quarter Performance Net Sales A Start According to Plan 2002 st Quarter 1 st 115.2 2003 st Quarter 1
More informationEnhancing Corporate Value
Goldman Sachs Twenty Sixth Annual Healthcare Conference Enhancing Corporate Value Eisai Co., Ltd. June 15, 2005 Please refer to the US Roadshow, June 2005 material in our WEB site for further information
More informationINVESTMENT FORUM December 4 th, 2006
1 INVESTMENT FORUM 2006 December 4 th, 2006 2 We Started as a Pioneer of Japanese Bio-Venture Company Sakuragaoka Laboratory (Started 1936) JUVELA (Vitamin E Pellet) 3 Codifying Our Corporate Concept in
More informationFY2009 First Quarter Financial Results. SUZUKI MOTOR CORPORATION August 3, 2009
FY2009 First Quarter Financial Results SUZUKI MOTOR CORPORATION August 3, 2009 Consolidated: Financial Summary Page 2 FY2009 1Q FY2008 4Q 09/4-6 09/1-3 Change FY2008 1Q 08/4-6 Change (Billion Yen) (A)
More informationConsolidated: Financial Summary
FY2010 First Quarter Financial Results SUZUKI MOTOR CORPORATION 3 August 2010 Consolidated: Financial Summary Page2 FY2010 1Q FY2009 1Q (2010/4-6) (2009/4-6) Change Net sales 656.3 577.1 +79.2 +13.7% Operating
More informationOmeprazole 10mg. Name, Restriction, Manner of administration and form OMEPRAZOLE omeprazole 10 mg enteric tablet, 30 (8332M) Max. Qty.
Omeprazole 10mg Name, Restriction, Manner of administration and form omeprazole 10 mg enteric tablet, 30 (8332M) Gastro-oesophageal reflux disease Name, Restriction, Manner of administration and form omeprazole
More informationRpts. GENERAL General Schedule (Code GE) Program Prescriber type: Dental Medical Practitioners Nurse practitioners Optometrists Midwives
Esomeprazole 20mg Name, Restriction, Manner of esomeprazole 20 mg enteric tablet, 30 (8886Q) (029W) Gastric ulcer Peptic ulcer Treatment Phase: Initial treatment The therapy must be for initial treatment
More informationRpts. GENERAL General Schedule (Code GE)
Pantoprazole 20mg Name, Restriction, Manner of administration and form Pantoprazole 20mg enteric tablet, 30 (8399C) Gastro-oesophageal reflux disease Name, Restriction, Manner of administration and form
More informationProton Pump Inhibitors (PPIs) (Sherwood Employer Group)
Proton Pump Inhibitors (PPIs) (Sherwood Employer Group) BCBSKS will review Prior Authorization requests Prior Authorization Form: https://www.bcbsks.com/customerservice/forms/pdf/priorauth-6058ks-st-ippi.pdf
More informationThird Quarter of FY2012 (March 2013) Earnings Results. Akihito Sakai, Managing Director Taisho Pharmaceutical Holdings January 31, 2013
Third Quarter of FY2012 (March 2013) Earnings Results Akihito Sakai, Managing Director Taisho Pharmaceutical Holdings January 31, 2013 Results for the 3rd Quarter of FY2012 (Yen B) FY2011 3Q(4-12) FY2012
More informationFirst Quarter Consolidated Financial Results Main Product Sales Update Main R&D Activities Reference. KYORIN Co., Ltd.
First Quarter Consolidated Financial Results for the Fiscal Year Ending March 31, 2010 Consolidated Financial Results Main Product Sales Update Main R&D Activities Reference Consolidated Financial Results
More informationONO PHARMACEUTICAL CO., LTD.
ONO PHARMACEUTICAL CO., LTD. February 6, 2006 Ono Pharmaceutical Co., Ltd. has announced its consolidated financial results for nine months ended December 31,. This First-Third Quarter Flash Report 2006
More informationONO PHARMACEUTICAL CO., LTD.
ONO PHARMACEUTICAL CO., LTD. February 4, 2005 Ono Pharmaceutical Co., Ltd. has announced its consolidated financial results for nine months ended December 31,. This First-Third Quarter Flash Report 2005
More informationFY2007 Consolidated Financial Overview
FY2007 Consolidated Financial Overview CHUGAI PHARMACEUTICAL CO., LTD. Executive Vice President and CFO Ryuzo Kodama January 30/31, 2008 Forward-Looking Statements This presentation may include forward-looking
More informationZegerid Capsules 20 mg and 40 mg Zegerid Powder for Oral Suspension 20 mg and 40 mg
Nasdaq: SNTS Safe Harbor This presentation may include forward-looking statements that are based on our management s beliefs and assumptions and on information currently available to our management. The
More informationMerrill Lynch Pharmaceutical, Biotechnology & Medical Device Conference New York, February 4, 2004
Merrill Lynch Pharmaceutical, Biotechnology & Medical Device Conference New York, February 4, 2004 Disclaimer 2 This presentation contains forward-looking statements, i.e., current estimates or expectations
More informationWalgreen Co. Reports Second Quarter 2010 Earnings Per Diluted Share of 68 Cents; Results Include 2 Cents Per Diluted Share of Restructuring Costs
Walgreen Co. Reports Second Quarter 2010 Earnings Per Diluted Share of 68 Cents; Results Include 2 Cents Per Diluted Share of Restructuring Costs Second quarter sales up 3.1 percent to record $17.0 billion
More informationSupernus Pharmaceuticals
Supernus Pharmaceuticals Jefferies 2016 Healthcare Conference May 2016 1 Safe Harbor Statement This presentation and other matters discussed today or answers that may be given to questions asked include
More information3Q FY2011 (Fiscal Year Ending March 31, 2012) Financial Results Presentation Eisai Co., Ltd.
3Q FY2011 (Fiscal Year Ending March 31, 2012) Financial Results Presentation Eisai Co., Ltd. February 2, 2012 Safe Harbor Statement Materials and information provided during this presentation may contain
More informationSummary of Results for the First Half of FY2015/3
Summary of Results for the First Half of FY2015/3 November 10, 2014 Tokyu Corporation (9005) http://www.tokyu.co.jp/ Contents Ⅰ.Executive Summary 2 Ⅱ.Conditions in Each Business 5 Ⅲ.Details of Financial
More informationDrug Class Monograph
Drug Class Monograph Class: Proton Pump Inhibitors Drugs: Aciphex Sprinkle (rabeprazole), Dexilant (dexlansoprazole), Lansoprazole, Nexium (esomeprazole capsule, esomeprazole granules), Omeprazole, Pantoprazole,
More informationThird Quarter Consolidated Financial Results
Third Quarter Consolidated Financial Results for the Fiscal Year Ending March 31, 2014 1. Overview of consolidated results 2. Highlights of Business Performance 3. Actual and Forecast of Main Subsidiary
More informationMerrill Lynch conference. Matthew Emmens, CEO Shire plc September 20, 2007
Merrill Lynch conference Matthew Emmens, CEO Shire plc September 20, 2007 THE SAFE HARBOR STATEMENT UNDER THE PRIVATE SECURITIES LITIGATION REFORM ACT OF 1995 Statements included herein that are not historical
More informationDS-8201 Strategic Collaboration
DS-8201 Strategic Collaboration DAIICHI SANKYO CO., LTD George Nakayama Chairman and CEO March 29, 2019 Forward-Looking Statements Management strategies and plans, financial forecasts, future projections
More informationConsolidated Financial Forecast for the Year Ending March 31,2014 Year ending March 31,2014 Net sales 148,300 $ 1,412,381 Operating income 27, ,
ONO PHARMACEUTICAL CO., LTD. February 4, 2014 Ono Pharmaceutical Co., Ltd. has announced its consolidated financial results for nine months ended December 31, 2013. This First - Third Quarter Flash Report
More informationH. LUNDBECK A/S. Teleconference. 10 August PM CET. Financial results Second quarter 2011
H. LUNDBECK A/S Teleconference 10 August 2011-2PM CET Financial results Second quarter 2011 Company disclaimer This presentation contains forward-looking statements that provide our expectations or forecasts
More information11 th Nomura INVESTMENT FORUM 2008
11 th Nomura INVESTMENT FORUM 2008 December 2, 2008 1 2 Safe Harbor Statement Materials and information provided during this presentation may contain socalled forward-looking statements. These statements
More informationUroplasty, Inc. Investor Update Canaccord Genuity Conference December 6, 2011
Uroplasty, Inc. Investor Update Canaccord Genuity Conference December 6, 2011 Forward Looking Statement This presentation includes forward-looking statements, including financial projections, relating
More informationConsolidated Financial Results for the Third Quarter of Fiscal Year 2017
Consolidated Financial Results for the Third Quarter of Fiscal Year 2017 1. Revenue Revenue totaled 200.6 billion, which was an increase of 11.7 billion (6.2%) from the corresponding period of the previous
More informationMeasuring and Evaluating Indicators of Appropriate Prescribing in Older. Populations
HRB PhD Scholar Division of Population Health Sciences RCSI Measuring and Evaluating Indicators of Appropriate Prescribing in Older Cost-Effective Proton Pump Populations Potential Strategies for more
More informationDeveloping Evidence-Based Best Practices for the Prescribing and Use of Proton Pump Inhibitors in Canada
Developing Evidence-Based Best Practices for the Prescribing and Use of Proton Pump Inhibitors in Canada Presented by: Sumeet R. Singh, COMPUS April 4, 2006 Background COMPUS Objective: To identify and
More informationProton Pump Inhibitors
Market DC Proton Pump Inhibitors Override(s) Prior Authorization Quantity Limit** Approval Duration Preferred PPI: No Prior Authorization required Preferred PPI quantity override: Lifetime Non-Preferred
More informationProton Pump Inhibitors. Description
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.50.01 Subject: Proton Pump Inhibitors Page: 1 of 6 Last Review Date: June 24, 2015 Proton Pump Inhibitors
More information1Q Fornebu, April 29, 2015 Luis Araujo and Svein Stoknes
1Q 2015 Fornebu, April 29, 2015 Luis Araujo and Svein Stoknes Forward-Looking Statements and Copyright This Presentation includes and is based, inter alia, on forward-looking information and statements
More informationProton Pump Inhibitors. Description. Section: Prescription Drugs Effective Date: July 1, 2014
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.09.01 Subject: Proton Pump Inhibitors Page: 1 of 7 Last Review Date: June 12, 2014 Proton Pump Inhibitors
More informationReview of Half Year 2010
Aiming i to Become a Top Japanese Pharmaceutical Company Review of Half Year 2010 CHUGAI PHARMACEUTICAL CO., LTD. President and CEO Osamu Nagayama July 22/23, 2010 Forward-Looking Statementst t Aiming
More informationStrategic Alliance Agreement for the Generic Business of Nichi-Iko Pharmaceutical Co., Ltd. and Eisai Co., Ltd.
Strategic Alliance Agreement for the Generic Business of Nichi-Iko Pharmaceutical Co., Ltd. and Eisai Co., Ltd. - Aiming to Create New Business Models and Expand Contribution to Patients - March 29, 2018
More informationDELICA D:5 ACTIVE GEAR 0
DELICA D:5 ACTIVE GEAR 0 1 1. FY2017 1Q Results 2. FY2017 1Q Results by Region 3. FY2017 Forecast 4. Initiatives for the Future FY2017 1Q Results Summary (vs. FY2016 1Q) (Apr-Jun 2016) (Apr-Jun 2017) (billion
More informationRegorafenib from Bayer Submitted to Health Authorities Seeking Approval in Second-Line Treatment of Liver Cancer
News Release Not intended for U.S. and UK Media Bayer AG Communications, Government Relations & Corporate Brand 51368 Leverkusen Germany Tel. +49 214 30-0 www.news.bayer.com Regorafenib from Bayer Submitted
More informationDeveloping & Commercializing Targeted Small Molecule Drugs in Cancer
Developing & Commercializing Targeted Small Molecule Drugs in Cancer SAFE HARBOR STATEMENT 2 Forward-looking statements made in the course of this presentation are made pursuant to the safe harbor provisions
More informationForward Looking Information
Vital Signs, Inc. Forward Looking Information Except for historical information discussed, the statements made today are forward-looking statements that involve risks and uncertainties. Investors are cautioned
More informationIncrease in revenues in line with full-year targets (+1.2%) Very strong growth of Oralair exc. USA (+26%) H revenues and results - 24 July 2014
Increase in revenues in line with full-year targets (+1.2%) Very strong growth of Oralair exc. USA (+26%) ( ) H1 2014 revenues and results - 24 July 2014 Forward-looking statement This presentation contains
More informationSG Cowen 23rd Annual Health Care Conference March 18, Shire Pharmaceuticals Group plc
SG Cowen 23rd Annual Health Care Conference March 18, 2003 Shire Pharmaceuticals Group plc THE SAFE HARBOR STATEMENT UNDER THE PRIVATE SECURITIES LITIGATION REFORM ACT OF 1995 Statements included herein
More informationInformation Meeting. March 7, 2014 Eisai Co., Ltd.
Information Meeting March 7, 2014 Eisai Co., Ltd. Safe Harbor Statement Forecast or target figures in this material are not official earnings guidance but present the midterm strategies, goals, and visions.
More informationOverview of consolidated results Main Product Sales Update Development pipelines. KYORIN Holdings, Inc.
First Quarter Consolidated Financial Results for the Fiscal Year Ending March 31, 2012 Overview of consolidated results Main Product Sales Update Development pipelines Reference Segment information for
More informationForward-Looking Statements
Investor Presentation May 2012 Forward-Looking Statements Statements contained herein that are not historical facts are forward-looking statements within the meaning of the Securities Act of 1933, as amended.
More informationBusiness Results. for the First Quarter of FY2016/3. August 4, 2015 (Tue.) NH Foods Ltd.
Business Results for the First Quarter of FY216/3 August 4, 215 (Tue.) NH Foods Ltd. Contents Contents I. Consolidated Business Results for FY216/3 1Q (Apr. Jun.) II. Outlook for FY216/3 III. Consolidated
More informationGlobal HPV Vaccine Market: Analysis By End-User (Male, Female), By Age Group (Adolescents, Adults) - By Region, By Country ( )
Global HPV Vaccine Market: Analysis By End-User (Male, Female), By Age Group (Adolescents, Adults) - By Region, By Country (2017-2022) By Region- North America, Europe, APAC and RoW By Country - United
More informationPPIs: Good or Bad? 1. Basics of PPIs. Gastric Acid Basics. Outline. Gastric Acid Basics. Proton Pump Inhibitors (PPI)
Outline Quick basics on Proton Pump Inhibitors (PPIs) PPIs: Good or Bad? What are potential risks of PPI therapy? How to approach your patients American Gastroenterology Association (AGA) recommendations
More informationSupplementary Data of Consolidated Financial Statements for the third quarter ended December 31, 2016
Supplementary Data of Financial Statements for the third quarter ended December 31, 2016 January 31, 2017 NITTO DENKO CORPORATION CONTENTS Page Business 1 Segment Information 2 Segment Information By Geographic
More informationFY 2017 (Ended March 31, 2018) Full Year Financial Results. Reference Data. May 15, Eisai Co., Ltd.
Securities Code: 4523 FY 2017 (Ended 2018) Full Year Financial Results Reference Data May 15, 2018 Eisai Co., Ltd. For Inquiries: Public Relations: TEL +81-(0)3-3817-5120 Investor Relations: TEL +81-(0)3-3817-3016
More informationSumitomo Pharmaceuticals reaches a basic agreement to merge with Dainippon Pharmaceutical
For immediate release November 25, 2004 Sumitomo Pharmaceuticals reaches a basic agreement to merge with Dainippon Pharmaceutical Sumitomo Chemical Co., Ltd. announced today that its subsidiary, Sumitomo
More informationSupernus Pharmaceuticals
Supernus Pharmaceuticals Investor Presentation March 2017 1 Safe Harbor Statement This presentation and other matters discussed today or answers that may be given to questions asked include forward-looking
More informationWELCOME TO ACTELION S AGM 2015
WELCOME TO ACTELION S AGM 2015 08 May 2015 Copyright 2015 Actelion Pharmaceuticals Ltd ACTELION S ANNUAL GENERAL MEETING 2015 MEETING STRUCTURE Opening Remarks Business Review 2014 Agenda & Proposals Jean-Pierre
More informationMerrill Lynch Healthcare Conference New York
Merrill Lynch Healthcare Conference New York Matthew Emmens Chief Executive Officer February 3, 2004 A Strategic Review Today and Beyond Clear Strengths Highly successful business model Strong pipeline
More information1 st Quarter of Fiscal 2015 Financial Results Conference Call. August 3, 2015
1 st Quarter of Fiscal 2015 Financial Results Conference Call August 3, 2015 1 SGS2020 Rolling Plan (Targets for FY2017) Our vision: Grow as a drug discovery-based pharmaceutical company FY2015 FY2016
More informationGlobal Prefilled Syringes Market: Trends, Opportunities and Forecasts ( )
Global Prefilled Syringes Market: Trends, Opportunities and Forecasts (2016-2021) By Material - Glass and Plastic By Filling Capabilities Single Chamber and Dual/Multiple Chamber By Major Applications
More informationQ2 FY2017 Business Results (April-September, 2017)
Mitsubishi Tanabe Pharma Corporation 田辺三菱製薬株式会社 Business Results (April-September, 2017) November 1, 2017 Eizo Tabaru Board Director, Managing Executive officer Business Results 1 Business Results Financial
More informationDIEBOLD NIXDORF AG AT GERMANY EQUITY FORUM
November 28, 2017 DIEBOLD NIXDORF AG AT GERMANY EQUITY FORUM Dr. Jürgen Wunram Agenda Diebold Nixdorf AG History and shareholder structure Market trends, strategy and progress of integration Diebold Nixdorf
More informationHigh use of maintenance therapy after triple therapy regimes in Ireland
High use of maintenance therapy after triple therapy regimes in Ireland K Bennett, H O Connor, M Barry, C O Morain, J Feely Department of Pharmacology & Therapeutics Department of Gastroenterology Trinity
More informationAstraZeneca and Daiichi Sankyo Launch Proton Pump Inhibitor Nexium 10 mg and 20 mg Granules for Suspension, Sachet, in Japan
AstraZeneca K.K. Daiichi Sankyo Co., Ltd. AstraZeneca and Daiichi Sankyo Launch Proton Pump Inhibitor Nexium 10 mg and 20 mg Granules for Suspension, Sachet, in Japan Osaka and Tokyo, Japan, April 18,
More informationDARA Reports Year-End 2012 Financial Results
April 1, 2013 DARA Reports Year-End 2012 Financial Results Company Provides a Commercial Portfolio and Development Pipeline Business Update RALEIGH, NC -- (MARKETWIRE) -- 04/01/13 -- DARA BioSciences,
More informationJP Morgan H&Q Healthcare Conference January 7, Shire Pharmaceuticals Group plc
JP Morgan H&Q Healthcare Conference January 7, 2003 Shire Pharmaceuticals Group plc Comment on the Safe Harbor Statement under the Private Securities Litigation Reform Act of 1995 The statements made during
More informationFujisawa Announce Financial Results for 1 st Quarter of FY 03/2005
July 30, 2004 Fujisawa Announce Financial Results for 1 st Quarter of FY 03/2005 Japan, July 30, 2004 Fujisawa Pharmaceutical Co., Ltd. today announced its financial results for the first quarter of fiscal
More informationSPHERIX ANNOUNCES FIRST QUARTER 2010 FINANCIAL RESULTS
SPHERIX Investor Relations Phone: (301) 897-2564 Email: info@spherix.com SPHERIX ANNOUNCES FIRST QUARTER 2010 FINANCIAL RESULTS BETHESDA, MD, May 21, 2010 - Spherix Incorporated (NASDAQ CM: SPEX), an innovator
More informationA world leader in allergy immunotherapy
A world leader in allergy immunotherapy Investor Relations presentation June 2017 1 I Investor Relations presentation I June 2017 ALK: Towards redefining treatment of severe allergies The commercial leader
More informationMyriad Genetics Fiscal First-Quarter 2019 Earnings Call 11/06/2018
Myriad Genetics Fiscal First-Quarter 2019 Earnings Call 11/06/2018 Copyright 2017 2018 Myriad Genetics, Inc., all rights reserved. www.myriad.com. 1 Forward Looking Statements Forward Looking Statements
More informationCowen Healthcare Conference
Cowen Healthcare Conference Shire plc March 9, 2010 Michael Cola President, Specialty Pharmaceuticals Our purpose We enable people with life-altering conditions to lead better lives 1 THE SAFE HARBOR STATEMENT
More informationNektar Investor & Analyst Call. Nektar & z Bristol-Myers Squibb Collaboration. February 14, 2018
Nektar Investor & Analyst Call Nektar & z Bristol-Myers Squibb Collaboration February 14, 2018 This presentation includes forward-looking statements regarding Nektar s proprietary drug candidates, the
More informationHyundai Motor Company 1 st Quarter 2011 Business Results. April 28, 2011
Hyundai Motor Company 1 st Quarter 2011 Business Results April 28, 2011 Cautionary Statement with Respect to Forward-Looking Statements In the presentation that follows and in related comments by Hyundai
More informationInvestor Presentation June 2012 NASDAQ: CEMI
Investor Presentation June 2012 NASDAQ: CEMI Forward-Looking Statements Statements contained herein that are not historical facts are forward-looking statements within the meaning of the Securities Act
More informationBALCHEM CORPORATION. Q Investor Relations Presentation
BALCHEM CORPORATION Q4 2017 Investor Relations Presentation Balchem Corporation Balchem develops, manufactures, and markets specialty ingredients that improve and enhance the health and well being of life
More information37 th ANNUAL JP MORGAN HEALTHCARE CONFERENCE
37 th ANNUAL JP MORGAN HEALTHCARE CONFERENCE January 2019 Safe Harbor Statement This presentation contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as
More informationShareholder Presentation Annual Meeting 2018
Shareholder Presentation Annual Meeting 2018 FY 18 HIGHLIGHTS Strong sales growth of 2 nd Gen TruScreen to China commenced during 4 th quarter. (50% of the year s sales were generated in the fourth quarter)
More informationPharmacy Coverage Guidelines are subject to change as new information becomes available.
PROTON PUMP INHIBITORS, NON-PREFERRED FORMS: ACIPHEX (rabeprazole sodium EC) oral tablet ACIPHEX SPRINKLE (rabeprazole sodium DR) oral capsule ESOMEPRAZOLE STRONTIUM (esomeprazole strontium DR) oral capsule
More informationPhotoCure ASA. Presentation. Results 1 Quarter 2004
PhotoCure ASA Presentation Results 1 Quarter 2004 7 th of May 2004 Progress towards sustained profitability Continued product roll out Metvix European sales continue to grow Final US approval for Actinic
More informationST. JUDE MEDICAL / THORATEC TRANSACTION HIGHLIGHTS July 22, 2015
ST. JUDE MEDICAL / THORATEC TRANSACTION HIGHLIGHTS July 22, 2015 1 FORWARD LOOKING STATEMENT This presentation contains forward-looking statements within the meaning of the Private Securities Litigation
More informationResults Presentation 2Q FY March Win-Partners Co., Ltd. (3183)
Results Presentation 2Q FY March 2018 Win-Partners Co., Ltd. (3183) 2Q results ending September 2017 Consolidated results summary ( mil)2q to Sep 2016 Sep 2017 YoY OE Sales 27,713 29,753 +7.4% 29,500 Operating
More informationFY 2018 (Ending March 31, 2019) Second Quarter Financial Results. Reference Data. November 1, Eisai Co., Ltd.
Securities Code: 4523 FY (Ending March 31, 2019) Second Quarter Financial Results Reference Data November 1, Eisai Co., Ltd. For Inquiries: Public Relations: TEL +81-(0)3-3817-5120 Investor Relations:
More informationThird Quarter 2015 Earnings Call. November 9, 2015
Third Quarter 2015 Earnings Call November 9, 2015 Forward-Looking Statements All of the statements in this presentation that are not statements of historical facts constitute forward-looking statements
More informationHALOZYME REPORTS SECOND QUARTER 2018 RESULTS
Contacts: Robert H. Uhl Managing Director Westwicke Partners, LLC 858-356-5932 robert.uhl@westwicke.com Laurie Stelzer 858-704-8222 ir@halozyme.com FOR IMMEDIATE RELEASE HALOZYME REPORTS SECOND QUARTER
More informationOVERALL SUMMARY OF THE SCIENTIFIC EVALUATION OF LOSEC AND ASSOCIATED NAMES (SEE ANNEX I)
ANNEX II SCIENTIFIC CONCLUSIONS AND GROUNDS FOR AMENDMENT OF THE SUMMARY OF PRODUCT CHARACTERISTICS, LABELLING AND PACKAGE LEAFLET PRESENTED BY THE EMEA 21 SCIENTIFIC CONCLUSIONS OVERALL SUMMARY OF THE
More informationResults Briefing Junichi Yoshii President & Representative Director
Fiscal Year Ending March 2010 Results Briefing Junichi Yoshii President & Representative Director May 14, 2010 1 Overview of Results (Consolidated) (Million yen) Net sales Operating profit Recurring income
More information4Q and Full Year 2017 Financial Results Call February 7, 2018
4Q and Full Year 2017 Financial Results Call February 7, 2018 Agenda Topic Welcome Opening Remarks 4Q 2017 Results Commercial Progress Question & Answer Speakers Amy Sullivan, SVP, Corporate Affairs Greg
More informationPRESCRIBING SUPPORT TEAM AUDIT: PROTON PUMP INHIBITOR PRESCRIBING REVIEW
PRESCRIBING SUPPORT TEAM AUDIT: PROTON PUMP INHIBITOR PRESCRIBING REVIEW DATE OF AUTHORISATION: AUTHORISING GP: PRESCRIBING SUPPORT TECHNICIAN: SUMMARY Dyspepsia refers to a broad range of symptoms related
More informationWalgreens (WAG) Analyst: Juan Fabres Fall 2014
Recommendation: Buy Target Price August 31, 2016: $77.57 1. Reasons for the Recommendation With the acquisition of Alliance Boots in Europe, Walgreens will be the first US pharmacy to operate retail stores
More informationUCB, with a strong year 2017, is reinforcing a solid foundation for investing in future growth
Brussels (Belgium), February 018 7:00 (CET) regulated information UCB Full Year Report 017: UCB, with a strong year 017, is reinforcing a solid foundation for investing in future growth Positive growth
More informationQ2 FY2017. Financial Results Presentation
Q2 FY2017 (Fiscal Year Ending March 31, 2018) Financial Results Presentation Eisai Co., Ltd. November 1, 2017 Safe Harbor Statement Materials and information provided during this presentation may contain
More informationAll Indiana Medicaid Prescribers and Pharmacy Providers
P R O V I D E R B U L L E T I N BT200148 NOVEMBER 28, 2001 To: All Indiana Medicaid Prescribers and Pharmacy Providers Subject: Note: The information in this bulletin regarding prior authorization payment
More informationPublic Assessment Report. Scientific discussion. Rabeprazolnatrium Torrent Pharma. 10 mg and 20 mg gastro-resistant tablets. Rabeprazole sodium
Public Assessment Report Scientific discussion Rabeprazolnatrium Torrent Pharma 10 mg and 20 mg gastro-resistant tablets Rabeprazole sodium DK/H/1819/001-002/DC This module reflects the scientific discussion
More informationMyriad Genetics Fiscal First-Quarter 2017 Earnings Call 11/01/2016
Myriad Genetics Fiscal First-Quarter 2017 Earnings Call 11/01/2016 1 Forward Looking Statements Forward Looking Statements Some of the information presented here today may contain projections or other
More informationResMed Inc. 36 th Annual J.P. Morgan Healthcare Conference
ResMed Inc. 36 th Annual J.P. Morgan Healthcare Conference Mick Farrell CEO January 8, 2018 Safe Harbor Statement Statements contained in this presentation that are not historical facts are forwardlooking
More informationProton Pump Inhibitors Drug Class Prior Authorization Protocol
Proton Pump Inhibitors Drug Class Prior Authorization Protocol Line of Business: Medi-Cal P&T Approval Date: November 15, 2017 Effective Date: January 1, 2018 This policy has been developed through review
More informationProton Pump Inhibitor De-prescribing Guidance
Amendment History Proton Pump Inhibitor De-prescribing Guidance VERSION DATE AMENDMENT HISTORY 1.0 2013 Previous version 2.0 September 2015 Comments Amendment to Flow chart and addition of Rationale page
More informationFor personal use only
HY18 Result Presentation 13 February 2018 Dig Howitt Brent Cubis CEO & President CFO HY18 Result highlights Strong momentum across developed markets continues Developed market unit growth up 12% Strengthening
More informationFY2017 Business Results (April, March, 2018)
Mitsubishi Tanabe Pharma Corporation 田辺三菱製薬株式会社 FY2017 Business Results (April, 2017 - March, 2018) May 10, 2018 Masayuki Mitsuka President and Representative Director FY2017 Business Results 1 FY2017
More informationBoiron Group confirms its forecasts for year 2008 : sales increase and growth in current operating income.
2008 FIRST QUARTER ACTIVITY IFRS - In thousands of Euros 2007 2007 2008 constant France (1) 0,000 66,087 65,728-0.5% -0.5% Europe excluding France 0,000 33,221 41,346 +24.5% +23.2% North America 0,000
More informationQ3 FY2017 Business Results (April-December, 2017)
Mitsubishi Tanabe Pharma Corporation 田辺三菱製薬株式会社 FY2017 Business Results (April-December, 2017) February 5, 2018 Eizo Tabaru Board Director, Managing Executive officer FY2017 Business Results (April-December,
More informationGlobal Hearing Aid Battery Market: Analysis By Battery Type, By Region, By Country: Trends, Opportunities, Restraints (2018 Edition) Forecast to 2022
Global Hearing Aid Battery Market: Analysis By Battery Type, By Region, By Country: Trends, Opportunities, Restraints (2018 Edition) Forecast to 2022 By Value (In Million USD) By Volume (In Million Units)
More informationSucampo Pharmaceuticals, Inc. Jefferies 2015 Healthcare Conference
Sucampo Pharmaceuticals, Inc. Jefferies 2015 Healthcare Conference June 3, 2015 Peter Greenleaf Chief Executive Officer Forward-Looking Statements This presentation contains "forward-looking statements"
More information